Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy

Keyphrases

• Spinal muscular Atrophy 100%
• Hepatotoxicity 100%
• AVXS-101 100%
• Onasemnogene Abeparvovec 100%
• Liver 66%
• Prednisolone 50%
• Managed Access Programme 50%
• Clinical Trials 33%
• Adverse Events 33%
• Gene Therapy 33%
• Alanine Aminotransferase 33%
• Aspartate Aminotransferase 33%
• Laboratory Data 33%
• Concomitant Medications 33%
• Acute Liver Injury 33%
• Bilirubin Concentration 33%
• SMN1 Gene 33%
• Immune Response 16%
• Autosomal Recessive 16%
• Clinical Data 16%
• Liver Injury 16%
• Treatment Duration 16%
• Young children 16%
• Motor Neuron Disease 16%
• Hepatotoxic 16%
• Result-oriented 16%
• Inherited Condition 16%
• Childhood-onset 16%
• Risk Mitigation 16%
• Drug-induced Liver Injury 16%
• Potential Drugs 16%
• Prednisolone Treatment 16%
• Adverse Event Data 16%
• Commercial Use 16%
• Serum Aminotransferases 16%
• Lay Summary 16%
• Toxicology Studies 16%
• Elevated Liver Function Tests 16%
• Survival Motor Neuron 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Spinal Muscular Atrophy 100%
• Hepatotoxicity 100%
• Onasemnogene Abeparvovec 100%
• Prednisolone 66%
• Adverse Event 50%
• Liver Injury 50%
• Clinical Trial 33%
• Aspartate Aminotransferase 33%
• Alanine Aminotransferase 33%
• Bilirubin 33%
• Aminotransferase 16%
• Toxic Hepatitis 16%
• Motor Neuron Disease 16%
• Survival Motor Neuron Protein 16%
• Toxicology 16%